These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3161934)

  • 61. Effects of testosterone, dihydrotestosterone, and estradiol on the impaired prolactin response to metoclopramide in the castrated rat.
    Zylber-Haran EA; Gershman H; Spitz IM
    Biol Reprod; 1981 Aug; 25(1):6-14. PubMed ID: 6456778
    [No Abstract]   [Full Text] [Related]  

  • 62. Endocrine effects of cyproterone acetate in patients with prostatic cancer.
    Isurugi K; Fukutani K; Ishida H; Hosoi Y
    J Urol; 1980 Feb; 123(2):180-3. PubMed ID: 7354512
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The basal levels of serum prolactin (PRL), luteinizine hormone (LH), follicle stimulating hormone (FSH), testosterone, thyroxine (T4), and cortisol in patients with pituitary mass: detection and evaluation.
    Namking M; Pavasuthipaisit K; Lerthamtewe W; Bunyaratavej S; Himathongkam T
    J Med Assoc Thai; 1981 Feb; 64(2):76-85. PubMed ID: 6785372
    [No Abstract]   [Full Text] [Related]  

  • 64. [Hirsutism treated with cyproterone acetate and ethinyl estradiol. Evaluation of the clinical effect].
    Pedersen IM; Nielsen DR; Larsen J; Starup J
    Ugeskr Laeger; 1985 Aug; 147(33):2594-6. PubMed ID: 2933858
    [No Abstract]   [Full Text] [Related]  

  • 65. Effect of cyproterone acetate on glucocorticoid secretion in patients treated for hirsutism.
    Holdaway IM; Croxson MS; Evans MC; France J; Sheehan A; Wilson T; Ibbertson HK
    Acta Endocrinol (Copenh); 1983 Oct; 104(2):222-6. PubMed ID: 6227191
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Morphofunctional study of the effects of fetal exposure to cyproterone acetate on the hypothalamo-pituitary-gonadal axis of adult rats.
    Rossi GL; Bestetti GE; Reymond MJ; Lemarchand-Béraud T
    Exp Brain Res; 1991; 83(2):349-56. PubMed ID: 1673659
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction.
    Gooren LJ; Harmsen-Louman W; van Kessel H
    Clin Endocrinol (Oxf); 1985 Feb; 22(2):201-7. PubMed ID: 3157511
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate.
    de Voogt HJ; Rao BR; Geldof AA; Gooren LJ; Bouman FG
    Prostate; 1987; 11(4):305-11. PubMed ID: 2960959
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer.
    Willemse PH; Dikkeschei LD; Mulder NH; van der Ploeg E; Sleijfer DT; de Vries EG
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):417-21. PubMed ID: 2968261
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Endocrine changes in male sexual deviants after treatment with anti-androgens, oestrogens or tranquillizers.
    Murray MA; Bancroft JH; Anderson DC; Tennent TG; Carr PJ
    J Endocrinol; 1975 Nov; 67(2):179-88. PubMed ID: 1107462
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of antiandrogen-estrogen treatment on sexual and endocrine parameters in hirsute women.
    Adamopoulos DA; Kampyli S; Georgiacodis F; Kapolla N; Abrahamian-Michalakis A
    Arch Sex Behav; 1988 Oct; 17(5):421-9. PubMed ID: 2975482
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy.
    Sawers RS; Randall VA; Ebling FJ
    Br J Dermatol; 1986 Sep; 115(3):269-74. PubMed ID: 2944535
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The management of female hirsutism with the anti-androgen agent cyproterone.
    Kwok PC; Correy JF; Senator GB
    Asia Oceania J Obstet Gynaecol; 1985 Jun; 11(2):233-40. PubMed ID: 4038178
    [No Abstract]   [Full Text] [Related]  

  • 74. Suitability of cyproterone acetate in the treatment of osteoporosis associated with athletic amenorrhea.
    De Crée C; Lewin R; Ostyn M
    Int J Sports Med; 1988 Jun; 9(3):187-92. PubMed ID: 2970444
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Deep venous thrombosis and antibodies to cyproterone acetate.
    Leroy O; Beuscart C; Senneville E; Visticot F; Tillie I; Brion M; Beaucaire G
    Lancet; 1990 Aug; 336(8713):509. PubMed ID: 1975016
    [No Abstract]   [Full Text] [Related]  

  • 76. Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer.
    Holub G; Lunglmayr G; Spona J
    Urol Res; 1981; 9(5):245-7. PubMed ID: 6458145
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of cyproterone acetate acutely administered on the pituitary-testicular axis.
    D'Agata R; Gulizia S; Vicari E; Aliffi A; Polosa P
    Horm Res; 1979; 11(3):109-14. PubMed ID: 488903
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comments on 'Conception during 'Diane' therapy--a successful outcome'.
    Bye P
    Br J Dermatol; 1986 Apr; 114(4):516. PubMed ID: 2938616
    [No Abstract]   [Full Text] [Related]  

  • 79. Liver structure and function during long-term treatment with cyproterone acetate.
    Kaiser E; Gruner HS
    Arch Gynecol; 1987; 240(4):217-23. PubMed ID: 2955749
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Simultaneous determination of cyproterone acetate and ethinylestradiol in tablets by derivative spectrophotometry.
    Souri E; Jalalizadeh H; Farsam H; Ghadiri R; Amanlou M
    Chem Pharm Bull (Tokyo); 2005 Aug; 53(8):949-51. PubMed ID: 16079526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.